Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 33,866

Document Document Title
WO/2024/051778A1
Provided herein are compounds having a Formula II-4, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds in inhibiting PI3K in a cell, or in treati...  
WO/2024/051784A1
Provided are a nitrogen-containing heterocyclic compound, a pharmaceutical composition thereof, and use thereof. The structure of the nitrogen-containing heterocyclic compound is represented by formula I. The nitrogen-containing heterocy...  
WO/2024/054956A1
The invention provides heterobifunctional compounds which may bind to both an androgen receptor and BRD4 (bromodomain- containing protein 4). Also provided are pharmaceutical compositions comprising the same and their use in treating dis...  
WO/2024/054955A1
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.  
WO/2024/051702A1
The present invention relates to a compound used as an inhibitor of a CDK4 kinase and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I), wherein the definitions of each group and ...  
WO/2024/054954A1
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.  
WO/2024/054624A1
Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD). (Formula (I))  
WO/2024/051668A1
Provided are a compound having a binding effect with an E3 ligase protein (CRBN) as represented by formula I and a use of the compound in the preparation of a drug for treating abnormal cell proliferation diseases.  
WO/2024/054540A1
The invention provides pyrazolo[1,5-a][1,3,5]benzotriazepinyl, pyrazolo[1,5-a]pyrido[3,4-f][1,3,5]triazepinyl and related tricyclic compounds that inhibit the activity of one or more kinases, more particularly the protein kinase leucine ...  
WO/2024/051590A1
The present invention relates to a salt type and crystal form of a benzazepine fused ring compound and use thereof, and in particular to a maleate of a compound represented by formula (I), the structure of the maleate being represented b...  
WO/2024/052820A1
The present invention is related to pharmaceutical composition of upadacitinib comprising upadacitinib or its pharmaceutically acceptable salt thereof, release controlling polymer, pH modifier and one or more pharmaceutical acceptable ex...  
WO/2024/054625A2
The present disclosure provides certain bifunctional compounds that cause degradation of K- ras G12D via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by K-ras G12D. Also provided are pharma...  
WO/2024/054953A1
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.  
WO/2024/051766A1
The present disclosure relates to a compound of formula (I) or a salt, an enantiomer, a diastereomer, an isotope-enriched analogue, a solvate, a prodrug or a polymorph thereof, and the use thereof. Further provided in the present disclos...  
WO/2024/049803A1
The present disclosure provides, in part, novel bicyclic heterocycle compounds of Formula (I), pharmaceutical compositions thereof, and methods for the treatment and prophylaxis of herpes viruses. Formula (I)  
WO/2024/046454A1
The present application relates to a heteroaryl-substituted pyridopyrrolidone derivative, and a pharmaceutical composition and the use thereof. The heteroaryl-substituted pyridopyrrolidone derivative has a structure as shown in formula (...  
WO/2024/049854A2
Provided are compounds of Formula (I) wherein X is selected from the group of ethanyl, ethenyl, ethynyl, and triazinyl; R1 is selected from the group of R1 is selected from the group of alkyl, alkoxy, cycloalkyl, -CH2-cycloalkyl, -O- cyc...  
WO/2024/046471A1
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...  
WO/2024/046420A1
The present disclosure relates to a fused bicyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a fused bicyclic compound as shown in general formula (I), a ...  
WO/2024/050370A1
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...  
WO/2024/050113A1
Methods, compositions, and devices are provided for use in controlling jet lag, chronotype, and/or circadian rhythm in a patient. Patients can be treated with a compound that binds NPL, to control the patient's jet lag, chronotype, and/o...  
WO/2024/049760A1
The present disclosure provides, in part, cyclic urea thiazolyl compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.  
WO/2024/048536A1
Provided is an organic EL element having high efficiency and long life even with a low voltage. Specifically, the present invention provides an organic EL element host material represented by general formula (1), an organic EL element ...  
WO/2024/050516A2
Provided herein are compounds, pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds or pharmaceutically acceptable salts thereof, kits containing these compounds or pharmaceutically acceptable salts t...  
WO/2024/050539A1
Provided herein are crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-di oxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde, compositions thereof, methods of preparation thereof, and methods of their uses.  
WO/2024/048758A1
This porous network complex is represented by formula (I) to (VIII), wherein: M2+ represents a divalent metal ion; M3+ represents a trivalent metal ion; L1a and L1b each represent a tridentate ligand having hexaazaphenalenyl; L2a and L2b...  
WO/2024/050297A1
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.  
WO/2024/050505A2
Methods and compositions for treating, inhibiting, and/or preventing diseases or disorders associated with aberrant bromodomain-containing protein 4 (BRD4) and phosphoinositide 3-kinase (PI3K) activity are disclosed.  
WO/2024/046406A1
Provided herein are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing suc...  
WO/2024/049977A1
Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are com...  
WO/2024/048519A1
Provided are: a pyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; a pharmaceutical use thereof, etc. A compou...  
WO/2024/048692A1
The present invention addresses the problem of providing an organic electroluminescent light-emitting element which has a long operating lifespan. The present invention is a light-emitting layer material for an organic electroluminescent...  
WO/2024/048809A1
The present invention relates to a novel heteroaryl derivative compound containing N, a method for preparing same, a pharmaceutical composition comprising same as an active ingredient, and use thereof. The compound of the present inventi...  
WO/2024/046342A1
Disclosed are benzo bicyclic compounds and the use thereof in drugs. Specifically, the present invention relates to novel benzo bicyclic compounds and pharmaceutical compositions comprising said compounds. The present invention further r...  
WO/2024/046409A1
The present invention relates to a heterocyclic compound, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention relates to a heterocyclic compound as shown in general formula (I), a preparat...  
WO/2024/046253A1
Provided in the present invention are a sodium channel regulator and the use thereof. The sodium channel regulator of the present invention has a brand-new structure and has an excellent in-vitro inhibitory effect on Nav 1.8. The compoun...  
WO/2024/045066A1
Provided are certain alkylidenyl carbamate compounds that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing such compo...  
WO/2024/048537A1
The present invention provides an organic EL element which has low voltage, high efficiency, and a long life. Provided are: an organic EL element containing a first host represented by general formula (1), a second host represented by ge...  
WO/2024/048436A1
Provided are: a resin composition comprising at least one resin selected from the group consisting of cyclic resins and precursors thereof, and compound A corresponding to at least one of compound a1 and compound a2; a cured product; a l...  
WO/2024/044649A2
Described herein, inter alia, are GTPase inhibitors and uses thereof.  
WO/2024/042361A1
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...  
WO/2024/041460A1
The present invention provides compounds of Formula (I) : wherein all of the variables are as defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for the...  
WO/2024/043341A1
The present invention provides a novel strain-promoted azide-alkyne cycloaddition (SPAAC) reaction. The present invention also provides a novel cycloalkyne derivative having a spiro ring as a cycloalkyne derivative that can be used in SP...  
WO/2024/042147A2
The invention relates to novel compounds having the general formula (I) wherein the substituents R1, R2, R3, R4 and X1 are as defined above, composition including the compounds and methods of using the compounds.  
WO/2024/042544A1
The present disclosure discloses a nickel catalyst of formula (I). The present disclosure also discloses a process of hydrogenation-dehydrogenation coupling catalyzed by catalyst of formula (I). Further, the present disclosure also discl...  
WO/2024/041589A1
Disclosed are a nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and use thereof. Specifically, the present invention provides a nitrogen-containing heterocyclic compound as represented b...  
WO/2024/044344A1
The invention provides pyridinylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...  
WO/2024/041183A1
The present application relates to an organic compound, an organic electroluminescent device, and an electronic apparatus. The organic compound of the present application has a structure represented by formula (1). By applying the organi...  
WO/2024/041608A1
The present invention relates to a crystal form of a compound N-cyclopropyl-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyri din-3-yl)methyl)piperazin-1-yl)pyridine carboxamide and a preparation method therefor, and the use thereof in the ...  
WO/2024/042480A1
The present invention relates to heteroaromatic compounds of formula (I), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof as antagonist at serotonin 5-HT2A receptor and agonist at serotonin 5-HT1A rec...  

Matches 51 - 100 out of 33,866